Abbott gets EUA for COVID-19, flu, RSV assay

2019 05 15 20 52 2340 Lab Pcr Tubes Dna 400

The U.S. Food and Drug Administration (FDA) has granted Abbott an emergency use authorization (EUA) for its Alinity m Resp-4-Plex molecular assay to detect and differentiate SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV) in one test.

The test only requires one swab (anterior nasal or nasopharyngeal) collected by a healthcare provider or an anterior nasal swab specimen that is self-collected at a healthcare location. The assay runs on Abbott's high-volume Alinity m system, which uses polymerase chain reaction (PCR) technology.

The EUA also covers the testing of asymptomatic COVID-19 individuals and a pooling claim to allow five samples to be tested at the same time.

The Alinity m Resp-4-Plex molecular assay already has the CE Mark and is available outside the U.S.

Page 1 of 23
Next Page